Property:Query string
"Query string" is a predefined property that describes the conditions of the query as a string and is provided by Semantic MediaWiki. This property is pre-deployed (also known as special property) and comes with additional administrative privileges but can be used just like any other user-defined property.
P
Publication: Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy +
[[Has subobject.Reference::Publication: Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy]]
B
Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy +
[[:Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy]]
Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy +
[[-Has subobject::Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy]] [[Drop-out::+]]
Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy +
[[-Has subobject::Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy]] [[Outcome name::+]]
Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy +
[[:Publication: Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy]]
P
Publication: Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group +
[[Has subobject.Reference::Publication: Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group]]
N
Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group +
[[:Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group]]
Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group +
[[-Has subobject::Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group]] [[Drop-out::+]]
Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group +
[[-Has subobject::Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group]] [[Outcome name::+]]
Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group +
[[:Publication: Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group]]
P
Publication: Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy +
[[Has subobject.Reference::Publication: Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy]]
Publication: Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial +
[[Has subobject.Reference::Publication: Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial]]
E
Emami et al. (2014): Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy +
[[:Emami et al. (2014): Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy]]
Emami et al. (2014): Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy +
[[-Has subobject::Emami et al. (2014): Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy]] [[Drop-out::+]]
Emami et al. (2014): Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy +
[[-Has subobject::Emami et al. (2014): Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy]] [[Outcome name::+]]
Y
Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial +
[[:Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial]]
Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial +
[[-Has subobject::Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial]] [[Drop-out::+]]
Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial +
[[-Has subobject::Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial]] [[Outcome name::+]]
Yap et al. (2017): Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial +
[[:Publication: Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial]]
H
Howells et al. (2011): Phase I randomised double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics and pharmacodynamics +
[[:Howells et al. (2011): Phase I randomised double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases - safety, pharmacokinetics and pharmacodynamics]]